

Preliminary program

PM

- 1.30 – 2.00: Welcome and introduction**
Andrew Kay, Chief Executive Officer
- 2.00 – 3.15: Prostate cancer: The importance of bone metastases and the future role of Alpha Pharmaceuticals**
Chris Parker, Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK and Principal Investigator of Algeta's phase III clinical trial with Alpharadin (ALSYMPCA)
- 3.15 – 3.25: Coffee break**
- 3.25 – 3.45: Clinical Trials**
Gillies O'Bryan-Tear, Chief Medical Officer
- 3.45 – 4.05: Potential to develop the alpha-pharmaceutical pipeline with thorium targeted alpha-therapy**
Thomas Ramdahl, Executive Vice President & Chief Technology Officer
- 4.05 – 4.15: Closing comments**
Andrew Kay, Chief Executive Officer
- 4.15 – 5.00: Drinks and canapés**